Multicenter Study of Isavuconazole MIC Distributions and Epidemiological Cutoff Values for the Cryptococcus neoformans-Cryptococcus gattii Species Complex Using the CLSI M27-A3 Broth Microdilution Method

Multilaboratory Study of Epidemiological Cutoff Values for Detection of Resistance in Eight Candida Species to Fluconazole, Posaconazole, and Voriconazole

(2014) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In Vitro Activities of Isavuconazole and Comparator Antifungal Agents Tested against a Global Collection of Opportunistic Yeasts and Molds

(2013) M. A. Pfaller et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cryptococcus neoformans-Cryptococcus gattii Species Complex: an International Study of Wild-Type Susceptibility Endpoint Distributions and Epidemiological Cutoff Values for Fluconazole, Itraconazole, Posaconazole, and Voriconazole

(2012) A. Espinel-Ingroff et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Extensive Genetic Diversity within the Dutch Clinical Cryptococcus neoformans Population

(2012) Ferry Hagen et al.   JOURNAL OF CLINICAL MICROBIOLOGY

Cryptococcus gattii in the United States: Clinical Aspects of Infection With an Emerging Pathogen

(2011) J. R. Harris et al.   CLINICAL INFECTIOUS DISEASES

In vitro antifungal susceptibility profiles and genotypes of 308 clinical and environmental isolates of Cryptococcus neoformans var. grubii and Cryptococcus gattii serotype B from north-western India

(2011) A. Chowdhary et al.   JOURNAL OF MEDICAL MICROBIOLOGY

A Diverse Population of Cryptococcus gattii Molecular Type VGIII in Southern Californian HIV/AIDS Patients

(2011) Edmond J. Byrnes et al.   PLoS Pathogens

In Vitro Antifungal Susceptibilities and Amplified Fragment Length Polymorphism Genotyping of a Worldwide Collection of 350 Clinical, Veterinary, and Environmental Cryptococcus gattii Isolates

(2010) F. Hagen et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America

(2010) John R. Perfect et al.   CLINICAL INFECTIOUS DISEASES

Antifungal susceptibility, serotyping, and genotyping of clinicalCryptococcus neoformansisolates collected during 18 years in a single institution in Madrid, Spain

(2010) Jesús Guinea et al.   MEDICAL MYCOLOGY

Isavuconazole: A Comprehensive Review of Spectrum of Activity of a New Triazole

(2010) George R. Thompson et al.   MYCOPATHOLOGIA

Mixed Infections and In Vivo Evolution in the Human Fungal Pathogen Cryptococcus neoformans

(2010) M. Desnos-Ollivier et al.   mBio

Emergence and Pathogenicity of Highly Virulent Cryptococcus gattii Genotypes in the Northwest United States

(2010) Edmond J. Byrnes et al.   PLoS Pathogens

A Long Journey from Minimum Inhibitory Concentration Testing to Clinically Predictive Breakpoints: Deterministic and Probabilistic Approaches in Deriving Breakpoints

(2009) A. Dalhoff et al.   INFECTION

Diversidad del complejo de especies Cryptococcus neoformans-Cryptococcus gattii

(2009) Marjan Bovers et al.   REVISTA IBEROAMERICANA DE MICOLOGIA

Antifungal Susceptibilities among Different Serotypes of Cryptococcus gattii and Cryptococcus neoformans

(2008) G. R. Thompson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY